Comparing Dose Levels to Placebo using a Continuous Outcome in a Small n, Sequential, Multiple Assignment, Randomized trial (snSMART)

References

• 107th Congress (2002), “Rare Diseases Act of 2002,” Pub L 107–280.
   Google Scholar
• Almirall, D., Compton, S. N., Rynn, M. A., Walkup, J. T., and Murphy, S. A. (2012), “SMARTer Discontinuation Trial Designs for Developing an Adaptive Treatment Strategy,” Journal of Child and Adolescent Psychopharmacology, 22, 364–374. DOI: 10.1089/cap.2011.0073.
   PubMed Web of Science ®Google Scholar
• Amery, W., and Dony, J. (1975), “A Clinical Trial Design Avoiding undue Placebo Treatment,” The Journal of Clinical Pharmacology, 15, 674–679. DOI: 10.1002/j.1552-4604.1975.tb05919.x.
   PubMed Web of Science ®Google Scholar
• Bell, S., and Smith, C. (2014), “A Comparison of Interventional Clinical Trials in Rare versus Non-rare Diseases: An Analysis of clinicaltrials.gov,” Orphanet Journal of Rare Diseases, 9, 1–11. DOI: 10.1186/s13023-014-0170-0.
   PubMed Web of Science ®Google Scholar
• Bhandari, M., Lochner, H., and Tornetta, P. (2002), “Effect of Continuous versus Dichotomous Outcome Variables on Study Power when Sample Sizes of Orthopaedic Randomized Trials are Small,” Archives of Orthopaedic and Trauma Surgery, 122, 96–98. DOI: 10.1007/s004020100347.
   PubMed Web of Science ®Google Scholar
• Donner, A., and Eliasziw, M. (1994), “Statistical Implications of the Choice between a Dichotomous or Continuous Trait in Studies of Interobserver Agreement,” Biometrics, 50, 550–555. DOI: 10.2307/2533400.
   PubMed Web of Science ®Google Scholar
• Egidi, L., Pauli, F., and Torelli, N. (2021), “Avoiding Prior–Data Conflict in Regression Models via Mixture Priors,” Canadian Journal of Statistics, 50, 491–510. DOI: 10.1002/cjs.11637.
   Web of Science ®Google Scholar
• Fang, F., Hochstedler, K., Tamura, R., Braun, T., and Kidwell, K. (2021), “Bayesian Methods to Compare Dose Levels with Placebo in a Small n, Sequential, Multiple Assignment, Randomized Trial,” Statistics in Medicine, 40, 963–977. DOI: 10.1002/sim.8813.
   PubMed Web of Science ®Google Scholar
• FDA (2015), “FDA Guidance for Industry (Draft),” Rare Diseases: Common Issues in Drug Development.
   Google Scholar
• Griggs, R. C., Batshaw, M., Dunkle, M., Gopal-Srivastava, R., Kaye, E., Krischer, J., Nguyen, T., Paulus, K., Merkel, P. A., and Rare Diseases Clinical Research Network. (2009), “Clinical Research for Rare Disease: Opportunities, Challenges, and Solutions,” Molecular Genetics and Metabolism, 96, 20–26. DOI: 10.1016/j.ymgme.2008.10.003.
   PubMed Web of Science ®Google Scholar
• Grimes, D., and Schulz, K. (2002), “An Overview of Clinical Research: The Lay of the Land,” The Lancet, 359, 57–61. DOI: 10.1016/S0140-6736(02)07283-5.
   PubMed Web of Science ®Google Scholar
• Gupta, S., Faughnan, M. E., Tomlinson, G. A., and Bayoumi, A. M. (2011), “A Framework for Applying Unfamiliar Trial Designs in Studies of Rare Diseases,” Journal of Clinical Epidemiology, 64, 1085–1094. DOI: 10.1016/j.jclinepi.2010.12.019.
   PubMed Web of Science ®Google Scholar
• Honkanen, V. E. A., Siegel, A. F., Szalai, J. P., Berger, V., Feldman, B. M., and Siegel, J. N. (2001), “A Three-Stage Clinical Trial Design for Rare Disorders,” Statistics in Medicine, 20, 3009–3021. DOI: 10.1002/sim.980.
   PubMed Web of Science ®Google Scholar
• Makubate, B., and Senn, S. (2010), “Planning and Analysis of Cross-Over Trials in Infertility,” Statistics in Medicine, 29, 3203–3210. DOI: 10.1002/sim.3981.
   PubMed Web of Science ®Google Scholar
• McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., Brown, K. K., Lynch, J. P., Goldberg, H. J., Young, L. R., Kinder, B. W., Downey, G. P., Sullivan, E. J., Colby, T. V., McKay, R. T., Cohen, M. M., Korbee, L., Taveira-DaSilva, A. M., Lee, H. S., Krischer, J. P., Trapnell, B. C.; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. (2011), “Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis,” New England Journal of Medicine, 364, 1595–1606. DOI: 10.1056/NEJMoa1100391.
   PubMed Web of Science ®Google Scholar
• Morita, S., Thall, P. F., and Müller, P. (2008), “Determining the Effective Sample Size of a Parametric Prior,” Biometrics, 64, 595–602. DOI: 10.1111/j.1541-0420.2007.00888.x.
   PubMed Web of Science ®Google Scholar
• Murphy, S. A. (2005), “An Experimental Design for the Development of Adaptive Treatment Strategies,” Statistics in Medicine, 24, 1455–1481. DOI: 10.1002/sim.2022.
   PubMed Web of Science ®Google Scholar
• Nason, M., and Follmann, D. (2010), “Design and Analysis of Crossover Trials for Absorbing Binary Endpoints,” Biometrics, 66, 958–965. DOI: 10.1111/j.1541-0420.2009.01358.x.
   PubMed Web of Science ®Google Scholar
• Rosner, G. L., Stadler, W., and Ratain, M. J. (2002), “Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents,” Journal of Clinical Oncology, 20, 4478–4484. DOI: 10.1200/JCO.2002.11.126.
   PubMed Web of Science ®Google Scholar
• Tamura, R. N., Krischer, J. P., Pagnoux, C., Micheletti, R., Grayson, P. C., Chen, Y.-F., and Merkel, P. A. (2016), “A Small n Sequential Multiple Assignment Randomized Trial Design for Use in Rare Disease Research,” Contemporary Clinical Trials, 46, 48–51. DOI: 10.1016/j.cct.2015.11.010.
   PubMed Web of Science ®Google Scholar
• Taveira-DaSilva, A. M., Stylianou, M. P., Hedin, C. J., Hathaway, O., and Moss, J. (2004), “Decline in Lung Function in Patients with Lymphangioleiomyomatosis Treated with or without Progesterone,” Chest, 126, 1867–1874. DOI: 10.1378/chest.126.6.1867.
   PubMed Web of Science ®Google Scholar
• Wei, B., Braun, T. M., Tamura, R. N., and Kidwell, K. M. (2018), “A Bayesian Analysis of Small n Sequential Multiple Assignment Randomized Trials (snSMARTs),” Statistics in Medicine, 37, 3723–3732. DOI: 10.1002/sim.7900.
   PubMed Web of Science ®Google Scholar